Literature DB >> 17562585

Fragile X syndrome: assessment and treatment implications.

Allan L Reiss1, Scott S Hall.   

Abstract

Fragile X syndrome (FraX) is the most common known cause of inherited mental impairment. FMR1 gene mutations, the cause of FraX, lead to reduced expression of FMR1 protein and an increased risk for a particular profile of cognitive, behavioral, and emotional dysfunction. The study of individuals with FraX provides a unique window of understanding into important disorders such as autism, social phobia, cognitive disability, and depression. This review highlights the typical phenotypic features of individuals with FraX, discussing the apparent strengths and weaknesses in intellectual functioning, as evidenced from longitudinal follow-up studies. It also discusses recent neuroanatomic findings that may pave the way for more focused disease-specific pharmacologic and behavioral interventions. This article describes the results of recent medication trials designed to target symptoms associated with FraX. It also describes some recent behavioral interventions that were conducted in our laboratory.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17562585     DOI: 10.1016/j.chc.2007.03.001

Source DB:  PubMed          Journal:  Child Adolesc Psychiatr Clin N Am        ISSN: 1056-4993


  36 in total

1.  Autism in fragile X syndrome: a category mistake?

Authors:  Scott S Hall; Amy A Lightbody; Melissa Hirt; Ava Rezvani; Allan L Reiss
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-08-01       Impact factor: 8.829

2.  A 'learning platform' approach to outcome measurement in fragile X syndrome: a preliminary psychometric study.

Authors:  S S Hall; J L Hammond; M Hirt; A L Reiss
Journal:  J Intellect Disabil Res       Date:  2012-04-25

Review 3.  Insights into brain development from neurogenetic syndromes: evidence from fragile X syndrome, Williams syndrome, Turner syndrome and velocardiofacial syndrome.

Authors:  E Walter; P K Mazaika; A L Reiss
Journal:  Neuroscience       Date:  2009-04-17       Impact factor: 3.590

4.  Supporting family adaptation to presymptomatic and "untreatable" conditions in an era of expanded newborn screening.

Authors:  Donald B Bailey; F Daniel Armstrong; Alex R Kemper; Debra Skinner; Steven F Warren
Journal:  J Pediatr Psychol       Date:  2008-03-30

5.  Distance delivery of a spoken language intervention for school-aged and adolescent boys with fragile X syndrome.

Authors:  Andrea McDuffie; Amy Banasik; Lauren Bullard; Sarah Nelson; Robyn Tempero Feigles; Randi Hagerman; Leonard Abbeduto
Journal:  Dev Neurorehabil       Date:  2017-09-28       Impact factor: 2.308

6.  Neuregulin 1-induced AKT and ERK phosphorylation in patients with fragile X syndrome (FXS) and intellectual disability associated with obstetric complications.

Authors:  Tamás Kovács; Boglárka Bánsági; Oguz Kelemen; Szabolcs Kéri
Journal:  J Mol Neurosci       Date:  2014-02-23       Impact factor: 3.444

7.  Biobehavioral indicators of social fear in young children with fragile X syndrome.

Authors:  Bridgette L Tonnsen; Svetlana V Shinkareva; Sara C Deal; Deborah D Hatton; Jane E Roberts
Journal:  Am J Intellect Dev Disabil       Date:  2013-11

Review 8.  Treatments for fragile X syndrome: a closer look at the data.

Authors:  Scott S Hall
Journal:  Dev Disabil Res Rev       Date:  2009

Review 9.  Fragile X: a family of disorders.

Authors:  Weerasak Chonchaiya; Andrea Schneider; Randi J Hagerman
Journal:  Adv Pediatr       Date:  2009

Review 10.  Systematic review of pharmacological treatments in fragile X syndrome.

Authors:  Jose-Ramon Rueda; Javier Ballesteros; Maria-Isabel Tejada
Journal:  BMC Neurol       Date:  2009-10-13       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.